利益相关者对可靠的人工智能对帕金森病管理的看法,使用协同创建方法:定性探索性研究
Beatriz Alves1, Ghada Alhussein1,2, Sara Riggare3
1Faculdade de Motricidade Humana, University of Lisbon, Lisbon, Portugal.
Journal of medical Internet research
|August 6, 2025
概括
帕金森病 (PD) 护理中的伦理人工智能 (AI) 需要优先考虑用户信任,透明度,公平性和人类监督. 这些原则对于开发可靠的AI驱动的PD诊断和管理数字健康解决方案至关重要.
科学领域:
- 神经科学是一个神经科学.
- 医疗信息学 医疗信息学
- 生物伦理学生物伦理学
背景情况:
- 帕金森病 (PD) 是全球增长最快的神经退行性疾病,对医疗保健构成重大挑战.
- 人工智能 (AI) 和可穿戴传感器为PD诊断,监测和预后提供了潜力.
- 伦理的人工智能采用需要诸如用户信任,透明度,公平性和人类监督等原则.
研究的目的:
- 探索有关AI在PD护理中的不同利益相关者的观点.
- 为PD指导道德AI驱动的数字健康解决方案的开发.
- 作为AI-PROGNOSIS项目的一部分,在PD的AI应用中强调透明度,数据安全性,公平性,偏见缓解和人类监督.
主要方法:
- 一种探索性的定性方法,使用与关键利益相关者共同创作研讨会.
- 涉及24名参与者:患有PD的个人,医疗保健专业人员,AI专家和生物伦理学家.
- 半结构化讨论的重点是AI在PD护理中的信任,公平,可解释性,自主性和心理影响.
主要成果:
- 出现了五个主要主题:人工智能信任和安全,人工智能透明度和教育,人工智能偏见和公平,人类监督以及人工智能的心理影响.
- 关键发现强调了数据安全,系统准确性,对人工智能技术的清晰解释和公平获取的需要.
- 重点是人工智能与人类的合作,以及人工智能过程中人类审查的重要作用.
结论:
- 实施强大的安全性,透明和可解释的AI模型以及偏见缓解策略至关重要.
- 整合人类监督和考虑人工智能的心理影响对于有效的PD护理至关重要.
- 为开发可靠和有效的AI驱动的PD诊断和管理数字解决方案,提供了可操作的指导.
相关概念视频
Parkinson's Disease: Treatment
375
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
375
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260


